Alder Biopharmaceuticals

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

Retrieved on: 
Tuesday, December 6, 2022
CMO, Annual report, Security (finance), PMO, Albireo, Growth, OLE, Institute of Liver and Biliary Sciences, COVID-19, Liver, EMA, Liver disease, Inflammation, FDA, Alder Biopharmaceuticals, Alkermes, Research and development, Drug development, Alagille syndrome, Neuroscience, IND World's Fair Line, BOLD, Hematology, AstraZeneca, GSK, DRS, Biliary atresia, Primary sclerosing cholangitis, Development, Itch, Patient, Physician, Vertex Pharmaceuticals, Arena Pharmaceuticals, Neurodegeneration, Infection, IND, Gastroenterology, EVP, Pharmaceutical industry, Insming, Pfizer, PFIC

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively. These appointments coincide with an important time for Albireo as the Company continues to deliver on clinical, regulatory, and commercialization milestones for Bylvay® (odevixibat) for indications potentially across three pediatric cholestatic liver diseases while advancing investigational compounds for adult liver and viral diseases.

Key Points: 
  • Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively.
  • Paul and Craig bring a depth and breadth of industry, academic and corporate experience to help take our Company to a new level,” said Ron Cooper, President and Chief Executive Officer of Albireo.
  • Most recently, Dr. Streck served as Chief Medical Officer at Arena Pharmaceuticals, a publicly traded biotechnology company acquired by Pfizer in March 2022.
  • Before that, Dr. Streck served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Pharmaceuticals in October 2020, and as the Chief Medical Officer of Insmed, advancing the company from clinical to commercial stage.

Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors

Retrieved on: 
Wednesday, January 19, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Xenon, Neurodegeneration, Doctor of Philosophy, Genzyme, Patient, Epilepsy, Alder, Biotechnology, Boston College, RNA, The Celator, Board of directors, UMIST, Initial public offering, Intellectual property, Â, Development, University of Manchester Institute of Science and Technology, Chemistry (relationship), Nasdaq, Therapy, Alder Biopharmaceuticals, Research and development, Liminal BioSciences, Scripps Research, Lists of diseases, Director, University, Board, Pharmaceutical industry, Vaccine, Research, Chemistry, Expansion, Technology

Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director.

Key Points: 
  • Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director.
  • He currently serves as interim Chief Scientific Officer and independent board member for Liminal Biosciences, as well as an independent board member for X4 Pharmaceuticals.
  • Most recently, Dr. Bridger served on the Board of Directors for Aquinox Pharmaceuticals from 2015 until the company merged with Neoleukin Therapeutics in 2019.
  • Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders.

Oerth Bio Expands Board of Directors with Appointment of Veteran Biotech Company Builder and Investor Thong Q. Le

Retrieved on: 
Tuesday, January 18, 2022
Technology, Agriculture, Natural Resources, Other Technology, Taste, Plant, Technology, Horizon Therapeutics, Harvard University, Government, Genome, WRF, Population, Knowledge, NASDAQ, Gilead Sciences, CEO, Intellectual property, LON, Bio, Nitrogen, University of Oxford, Lundbeck, Templeton College, Oxford, Acquisition, Crop protection, Animal, Fungus, Industry, ALSP, Therapy, Alder Biopharmaceuticals, Minimal genome, Immunity, Agriculture, Environment, Amgen, Attune, Senior, Management, Pharmaceutical industry, Fine chemical, Video game console, Bayer, the Attune™ Platform, Oerth Bio, THE ATTUNE™ PLATFORM, OERTH BIO

Oerth Bio (pronounced Earth), an agricultural biotech company pioneering targeted protein modulation for plant health applications, has appointed Thong Q.

Key Points: 
  • Oerth Bio (pronounced Earth), an agricultural biotech company pioneering targeted protein modulation for plant health applications, has appointed Thong Q.
  • We are pleased to welcome Thong to the board of Oerth Bio, said John Dombrosky, Chief Executive Officer of Oerth Bio.
  • He will prove invaluable to Oerth Bio in supporting many of our decisions as the company further matures.
  • Le brings considerable experience to the board of Oerth Bio.

PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors

Retrieved on: 
Tuesday, October 26, 2021
Strategic management, Prostate, Adoption, Intersection, Lower urinary tract symptoms, Alder Biopharmaceuticals, Allergan, BPH, LUTS, Board, Growth, Man, Benign prostatic hyperplasia, Solution, Nasdaq, Therapy, Chief commercial officer, Health, GLOBE, Board of directors, Management

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors.
  • Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals.
  • "I am pleased to join PROCEPT BioRobotics Board of Directors and be a part of a company dedicated to improving the lives of men suffering from lower urinary tract symptoms (LUTS) due to BPH.
  • With the appointment of Ms. Sandoval, the Board of Directors of PROCEPT BioRobotics Corporation increased the number of directors on the Board to nine members.

Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance

Retrieved on: 
Tuesday, September 14, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Aston, Upjohn, R, National, Patient, Alder Biopharmaceuticals, Deloitte, IND, SVP, RAPS, Merck, CVS, Alder, Acalabrutinib, Aston University, Molecular Omics, CMC, Lundbeck, Merck & Co., PDA, Pharmacokinetics, Therapy, University of Washington Department of Bioengineering, NASDAQ, Salk Institute for Biological Studies, Acquisition, Cancer, Wharton School of the University of Pennsylvania, Drug discovery, BTK, Infection, Pharming, Rensselaer Polytechnic Institute, MBA, San Diego State University, Accounting, AstraZeneca, Business, Lengo Petroglyphs, University, Drug development, Technology, Pharmacology, Pharmacy, University of Pennsylvania, Industry, Drug metabolism, Handbook, ACS, Pharmaceutical industry

Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Companys executive management team.

Key Points: 
  • Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Companys executive management team.
  • Prior to Amgen, Paul served as Executive Director of Preclinical Drug Metabolism at Merck Research Laboratories.
  • Paul is the editor of the Handbook of Drug Metabolism (2019) and has published extensively in the field.
  • Eric Gruff, Ph.D., is SVP of CMC at Lengo Therapeutics.

Endpoint Health Announces Renowned Industry Leaders as Strategic Advisors

Retrieved on: 
Wednesday, August 25, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Microbiology, Muscle, Sepsis, General manager, Liver, University School, Critical Care Medicine (journal), Heroes of Chemistry, Twitter, Therapy, Social media, RNA interference, Rheumatoid arthritis, Leadership, Artificial intelligence, Efficiency, Research, Regeneron Pharmaceuticals, Doctor of Philosophy, Agouron, Assistant, Union of Sales and Marketing Professionals, Sunovion, Genentech, Roche Diagnostics, Senior, Alder Biopharmaceuticals, Genomics, Marketing, Patient, Development, CEO, Amgen, Lung, American Chemical Society, Neoplasm, Roche, Arrowhead Pharmaceuticals, Virology, Eli Lilly, Social, Infection, Health, MD, Medical device, Medical imaging, Pharmaceutical industry

Endpoint Health, a precision-first therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced the appointment of several strategic advisors.

Key Points: 
  • Endpoint Health, a precision-first therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced the appointment of several strategic advisors.
  • These renowned industry leaders will provide counsel on the companys efforts to advance precision therapeutics for immune-driven illnesses.
  • We are pleased to welcome these distinguished leaders as strategic advisors to Endpoint Health, said Jason Springs, co-founder and Chief Executive Officer at Endpoint Health.
  • Individuals who will be joining Endpoint Health as strategic advisors include:
    Paul Brown, PhD, former Global Head of Roche Molecular Solutions.

Immunomedics Appoints Robert W. Azelby to Board of Directors

Retrieved on: 
Thursday, February 27, 2020
Life sciences, Articles, Biotechnology, Immunomedics, Alder Biopharmaceuticals, Lundbeck, Antibody-drug conjugate, Biopharmaceutical

MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Companys board of directors.

Key Points: 
  • MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Companys board of directors.
  • I am excited to join Immunomedics at an inflection point as the Company is preparing for its first potential commercial launch in its history, said Mr. Azelby.
  • Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc., which was acquired by H. Lundbeck A/S in October 2019.
  • Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby holds a B.A.

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors

Retrieved on: 
Wednesday, December 18, 2019
Alder Biopharmaceuticals, Industries, Life sciences, Biotechnology, NASDAQ Biotechnology Index

Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Global Blood Therapeutics, Inovio Pharmaceuticals, Inc. and Myokardia.

Key Points: 
  • Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Global Blood Therapeutics, Inovio Pharmaceuticals, Inc. and Myokardia.
  • She previously served on the board of directors of various other life science companies, including Alder Biopharmaceuticals, Durata Therapeutics, St. Jude Medical and Medivation.
  • "Wendy brings a unique breadth of experience in pre-and post-launch commercialization of pharmaceuticals to our Board," said John Diekman, Ph.D., Chairman of IDEAYA's Board of Directors.
  • "I'm delighted to join IDEAYA's Board of Directors to help advance IDEAYA's vision of improving lives through transformative precision medicines.

Alder Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Alder Biopharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact The Firm – ALDR

Retrieved on: 
Monday, September 16, 2019
Alder Biopharmaceuticals, Halper, Securities fraud, Articles, Humans

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) to H. Lundbeck A/S(Lundbeck) is fair to Alder shareholders.

Key Points: 
  • NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) to H. Lundbeck A/S(Lundbeck) is fair to Alder shareholders.
  • On behalf of Alder shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • If you are an Alder shareholder and would like to discuss your legal rights and options, please visit Alder BioPharmaceuticals Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected] .
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash

Retrieved on: 
Monday, September 16, 2019
Life sciences, Articles, Pharmaceutical industry, Biopharmaceutical, Biotechnology, Pharmacy, Alder Biopharmaceuticals, Medication, Migraine, Eptinezumab

The transaction is valued at up to USD 1.95 billion (approximately DKK 13 billion) net of cash, on a fully diluted basis.

Key Points: 
  • The transaction is valued at up to USD 1.95 billion (approximately DKK 13 billion) net of cash, on a fully diluted basis.
  • Alder is a clinical-stage biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies.
  • Migraine prevention is an attractive indication for us that leverages our specialized commercial expertise in delivering medicines for brain diseases.
  • Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies.